Nathan Falk, MD, MBA, FAAFP - Making Sense of Type 2 Inflammation Crosstalk in Chronic Diseases: Perspectives on Improving Emergency and Primary Care Collaboration

Please visit answersincme.com/ZYD860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by April W. Armstrong, MD, MPH. In this activity, an expert in dermatology discusses best practices to diagnose and manage bullous pemphigoid (BP). Upon completion of this activity, participants should be better able to: Review the process for diagnosing patients with BP; Assess the evidence for the use of biologics targeting type 2 inflammation in the treatment of BP; and Outline the clinical implications of the evidence for the treatment of BP with biologics targeting type 2 inflammation.

Please visit answersincme.com/GFY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Vishal A. Patel, MD; and Jonathan S. Zager, MD, FACS, FSSO. In this activity, experts in cutaneous oncology discuss the evolving role of gene expression profiling (GEP) tests in refining risk assessment and supporting individualized, multidisciplinary management strategies for patients with melanoma. Upon completion of this activity, participants should be better able to: Identify the clinical rationale for using GEP tests to stratify the risk of disease progression in patients with cutaneous melanoma; Review the clinical evidence, including guideline-supported data, for GEP tests to stratify disease progression risk in patients with cutaneous melanoma; Formulate multidisciplinary strategies for incorporating the results of GEP tests into risk-based management of patients with cutaneous melanoma; and Outline patient-centered approaches to integrating GEP tests into the management of patients with cutaneous melanoma at risk of metastasis.

Please visit answersincme.com/WWD860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Peter Lio, MD, FAAD; Sarah L. Chamlin, MD; and Heather Moery. In this activity, experts in pediatric atopic dermatitis discuss earlier use of systemic therapy to improve long-term disease control and patient-centered outcomes. Upon completion of this activity, participants should be better able to: Identify the need for systemic therapy among pediatric patients with moderate-to-severe atopic dermatitis (AD); Recognize pediatric patients with moderate-to-severe AD for whom biologic therapy is an appropriate, evidence-based option; Review shared decision-making considerations regarding biologic therapy for pediatric patients with moderate-to-severe AD; and Integrate strategies to optimize biologic treatment for pediatric patients with moderate-to-severe AD.

Please visit answersincme.com/860/MED-ONC-03814-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Neil D. Gross, MD, FACS; Nikhil I. Khushalani, MD; and Emily S. Ruiz, MD, MPH. In this activity, leading skin cancer experts guide an interactive, multidisciplinary case-based discussion on optimizing (neo)adjuvant immunotherapy for high-risk, resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Apply the latest clinical trial data and guideline recommendations to treatment planning for patients with high-risk, resectable CSCC; Recognize when to incorporate systemic neoadjuvant and adjuvant immunotherapy in patients with CSCC based on clinical and pathological features; and Propose strategies to optimize care for patients with high-risk CSCC through the evidence-based use of neoadjuvant and adjuvant immunotherapy within multidisciplinary care plans.

Please visit answersincme.com/860/2026-MC-001884-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Marc Serota, MD; Kristin Sokol, MD, MS, MPH; and Michelle Tarbox, MD. In this activity, experts in chronic spontaneous urticaria (CSU) discuss strategies to reduce diagnostic delays and how to personalize care beyond antihistamines. Upon completion of this activity, participants should be better able to: Recognize the impact of delayed diagnosis on disease control in patients with CSU; Review key inflammatory pathways—including type 2 inflammation—in CSU pathogenesis and how targeted therapies modulate them; Assess the latest clinical data for targeted therapies for the treatment of CSU; and Apply evidence-based strategies to personalize the management of antihistamine-refractory CSU.